MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
腺病毒疫苗治疗结肠癌的机制
基本信息
- 批准号:6410215
- 负责人:
- 金额:$ 22.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-01-12 至 2001-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The major goal of this project is to identify an optimal adenovirus-
based vaccination strategy against homologue (mEGP) of the human
colorectal carcinoma-associated GA733 antigen. Since mice express mEGP on
normal tissues (similar to GA733 Ag in humans), this animal model allows
testing of the vaccine in an immunologically tolerant host and evaluation
of potential toxicity. These studies will optimize the ability of this
vaccine to overcome tolerance to this tumor antigen in settings that
closely mimic patients with colon cancer. Therefore, they will have an
impact on the initial human clinical trial (see Project 3, Aim 2) and will
provide the basis for the testing of improved human colon cancer vaccines
in the near future. We have prepared an adenovirus-based mEGP vaccine and
have already shown that it can induce tumor protection in the mouse when
used in combination with interleukin-2 (IL-2). This is the basis for our
proposed series of experiments. Our initial experiments will address
issues of immediate clinical relevance, i.e., administration of the
vaccine by a cutaneous route, the need for one versus two doses of the
vaccine, and the appropriate use of cytokine. Having identified parameters
that limit or enhance our vaccine in a subcutaneous tumor model, we will
than address whether our vaccination strategy is effective against more
advanced and metastatic disease. This will provide us with the opportunity
to improve our vaccine by studying the effects of different booster
strategies, the use of other cytokines and the use of functionally active
fragments (from Project 1) of mEGP. Having optimized our vaccine, we will
study its mechanism of action by defining the target cells through which
the adenovirus elicits anti-mEGP immunity, the role of the adenoviral
proteins in the induction of the immune response, and the cell types that
contribute to the effectiveness of the immune response.
本课题的主要目标是确定一种最佳的腺病毒
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHEN L. ECK其他文献
STEPHEN L. ECK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEPHEN L. ECK', 18)}}的其他基金
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
腺病毒疫苗治疗结肠癌的机制
- 批准号:
6563875 - 财政年份:2002
- 资助金额:
$ 22.84万 - 项目类别:
INHIBITION OF T CELLS BY A TUMOR ASSOCIATED PROTEIN
肿瘤相关蛋白对 T 细胞的抑制
- 批准号:
6258523 - 财政年份:2001
- 资助金额:
$ 22.84万 - 项目类别:
TREATMENT OF RECURRENT/PROGRESSIVE MALIGNANT GLIOMA WITH H5 010CMVHINF ADENOVIRUS
用 H5 010CMVHINF 腺病毒治疗复发性/进行性恶性神经胶质瘤
- 批准号:
6565876 - 财政年份:2001
- 资助金额:
$ 22.84万 - 项目类别:
TREATMENT OF RECURRENT/PROGRESSIVE MALIGNANT GLIOMA WITH H5 010CMVHINF ADENOVIRUS
用 H5 010CMVHINF 腺病毒治疗复发性/进行性恶性神经胶质瘤
- 批准号:
6468126 - 财政年份:2000
- 资助金额:
$ 22.84万 - 项目类别:
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
腺病毒疫苗治疗结肠癌的机制
- 批准号:
6300546 - 财政年份:2000
- 资助金额:
$ 22.84万 - 项目类别:
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
腺病毒疫苗治疗结肠癌的机制
- 批准号:
6103374 - 财政年份:1999
- 资助金额:
$ 22.84万 - 项目类别:
MECHANISMS OF ADENOVIRUS VACCINES FOR COLON CANCER
腺病毒疫苗治疗结肠癌的机制
- 批准号:
6269841 - 财政年份:1998
- 资助金额:
$ 22.84万 - 项目类别:
DEVELOPMENT, CHARACTERIZATION, AND PRODUCTION OF A B7 ADENOVIRUS VECTOR
B7 腺病毒载体的开发、表征和生产
- 批准号:
6103017 - 财政年份:1997
- 资助金额:
$ 22.84万 - 项目类别:
相似海外基金
Active immunization mouse model by cN1A peptides
cN1A肽主动免疫小鼠模型
- 批准号:
18K15370 - 财政年份:2018
- 资助金额:
$ 22.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an efficient oocyte collection method using active immunization against inhibin in cynomolgus monkeys.
使用食蟹猴主动免疫抑制素开发有效的卵母细胞收集方法。
- 批准号:
17H06766 - 财政年份:2017
- 资助金额:
$ 22.84万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Passive and Active Immunization for Pneumocystis
肺孢子虫的被动和主动免疫
- 批准号:
9182862 - 财政年份:2015
- 资助金额:
$ 22.84万 - 项目类别:
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
- 批准号:
8136035 - 财政年份:2007
- 资助金额:
$ 22.84万 - 项目类别:
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
- 批准号:
7921670 - 财政年份:2007
- 资助金额:
$ 22.84万 - 项目类别:
Can passive or active immunization alter the course of infection with circoviral DNA?
被动或主动免疫可以改变圆环病毒 DNA 的感染过程吗?
- 批准号:
306844-2004 - 财政年份:2007
- 资助金额:
$ 22.84万 - 项目类别:
Special Research Opportunity Program - Project
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
- 批准号:
7341002 - 财政年份:2007
- 资助金额:
$ 22.84万 - 项目类别:
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
- 批准号:
7502083 - 财政年份:2007
- 资助金额:
$ 22.84万 - 项目类别:
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
- 批准号:
7679096 - 财政年份:2007
- 资助金额:
$ 22.84万 - 项目类别:
Passive-Active Immunization Strategies Against Pediatric AIDS
针对儿童艾滋病的被动-主动免疫策略
- 批准号:
7065729 - 财政年份:2006
- 资助金额:
$ 22.84万 - 项目类别: